These data, combined with an overexpression of PDX-1 seen in human specimens of pancreatic neuroendocrine tumors and nesidioblastosis, support the role of PDX-1 as a potential novel therapeutic target using this novel RNAi platform [28]. The gene discussed is PDX1; the disease is familial hyperinsulinism.